Genor Biopharma Co.,Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Genor Biopharma Co.,Ltd. - overview
Established
2007
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Based in China, Genor Biopharma Co. ,Ltd. focuses on the development and commercialization of innovative biopharmaceutical products, primarily targeting antibody therapies for various diseases. Genor Biopharma Co.
,Ltd. specializes in biopharmaceutical development and was founded in 2007 in Shanghai, China. The company was involved in a MERGER in October 2020, raising USD 677. 00 mn from Edding Genor Group Holdings Limited.
The firm has completed a total of 9 deals, with the most recent deal dated October 7, 2020. The CEO is Feng Guo, who has a history of leadership in the biopharmaceutical sector. Genor Biopharma Co. Ltd specializes in developing and commercializing biopharmaceutical products, particularly innovative monoclonal antibody therapies aimed at treating diseases such as cancer and autoimmune disorders.
Their products are designed to engage specific biological targets to enhance therapeutic efficacy while minimizing adverse effects. Genor serves a global customer base, including hospitals and pharmaceutical distributors, with products marketed across North America, Europe, and Asia. In 2020, Genor Biopharma Co. Ltd generated revenue of USD 1,497,981.
40, with an EBITDA of -USD 119,932,484. 50 for the year. Genor Biopharma Co. Ltd plans to launch new products focused on innovative monoclonal antibodies, with specific details expected in upcoming announcements.
The company aims to expand into new markets, particularly in Europe and North America, by the end of 2023. The funds raised during the recent IPO, amounting to HKD 2. 8776 billion, will support these initiatives and enhance their product pipeline in preparation for broader market entry.
Current Investors
Edding Genor Group Holdings Limited, Yingke Private Equity, Temasek Holdings
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.genorbio.com
Company Stage
Merged
Total Amount Raised
Subscriber access only
Genor Biopharma Co.,Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Completed | Edding Pharm, Genor Biopharma Co.,Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.